CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Otsuka Pharmaceutical›
Library
Otsuka Pharmaceutical

Otsuka Pharmaceutical

Part ofOtsuka Holdings Co.

Otsuka Pharmaceutical is a healthcare group pairing prescription medicines for psychiatric and neurologic disease with consumer nutrition products.

Operating headquarters
Chiyoda-Ku, Tokyo, JP🇯🇵
Founded
1964
Loading
Overview
M & A
Relationships
Compare
Employees
News
Library

Otsuka Pharmaceutical - Library

otsuka.co.jp·Crawled Oct 9, 2026·

Topics

Publication type

Content origin
Row density

Product

6 pages
  1. For People Using Our Medicines/for-patients

    For the proper use of medicines. Learn about products from Otsuka Pharmaceutical’s healthcare business.

  2. Healthcare Professionals/for-healthcare-professionals

    This is the page for information for healthcare professionals on Otsuka Pharmaceutical’s website.

  3. Let’s make dementia a less lonely disease./dementia

    Otsuka Pharmaceutical’s comprehensive efforts to create a society where people with dementia and those without it can live life on their own terms.

  4. Medical-Related Business/pharmaceutical-business

    Create things that resonate around the world without imitation. This is the Medical-Related Business page of Otsuka Pharmaceutical.

Blog

6 pages
  1. Blog/

    This is Otsuka Pharmaceutical’s official account. We share information and initiatives that support health, as well as the thoughts and stories of our employees. We’ll share stories that inspire people to think about their health and help them feel closer to Otsuka Pharmaceutical.

  2. Health and Illness/health-and-illness

    To help as many patients as possible recover and contribute to the health of as many people as possible. We explain a variety of topics about health and illness in an easy-to-understand way. This is Otsuka Pharmaceutical’s “Health and Illness” page.

  3. New: What is Otsuka Pharmaceutical’s “/zeroz”? The story behind the launch of a new brand, born from 13 years of research into ingredients that “harness oxygen”/n/n0dea4782af5c

    Launched in 2026, the new brand “/zeroz.” Containing kaempferol, a plant-derived ingredient that harnesses oxygen, “/zeroz” is a self-conditioning food that supports daily well-being by working with the body’s natural capabilities.   Here, we introduce the story behind the launch of “/zeroz” and an overview of the product! The origins of /zeroz: What does the idea of “Active Inner Resource” mean? Rather than “supplementing the body with nutrients and functions from outside,” the idea is to “work with the capabilities people naturally have and draw them out.” Our bodies are made up of various tissues and...

  4. Nutraceuticals Business Group, Mass Retail Department: When we’re able to deliver unique proposals and initiatives made possible by Otsuka Pharmaceutical’s two businesses—the NC-related business and the healthcare-related business—it gives us an unparalleled sense of accomplishment. View on note/n/n0b2edd52fba6

    In the “Recruiting Team Presents” series on Otsuka Pharmaceutical’s official note, employees share their candid experiences with people currently job hunting. Otsuka Pharmaceutical has a “healthcare-related business,” which covers everything from disease diagnosis to treatment, and a “Nutraceuticals (NC)-related business,” which offers products such as Pocari Sweat and CalorieMate to support daily health and well-being. This time, we introduce the career of Takeuchi, who works in the NC Business Division’s Mass Retail Department. 【About Takeuchi】 Takeuchi played baseball from elementary school through university. At university, he led a baseball club and enjoyed a fulfilling student life with his teammates. After joining Otsuka Pharmaceutical as a new graduate in 2021, he worked in a regional...

Press

5 pages
  1. 2026.09.18 Healthcare Business: FACEDUO launches new content, “Understanding a New Perspective on Dementia” — Supporting greater understanding of a new perspective on dementia, in which people can continue to live in their own way even after developing dementia/company/newsreleases/2026/20260918_1.html
  2. 2026.09.22 Healthcare Business: Positive results from the Phase 3 trial of ulefnersen for amyotrophic lateral sclerosis (ALS) caused by FUS mutations — Steady progress toward realizing gene-targeted treatment for people with FUS-ALS/company/newsreleases/2026/20260922_1.html
  3. 2026.09.24 Healthcare Business: Additional analyses from the Phase 3b trial of SIMTRIYO® (centanafadine), a treatment for attention-deficit/hyperactivity disorder (ADHD), presented at Psych Congress 2026 — Consistent improvements were confirmed across a broad range of associated symptoms, including executive function impairment and emotional dysregulation, as well as ADHD and anxiety symptoms, in adults with ADHD and comorbid anxiety disorders./company/newsreleases/2026/20260924_1.html
  4. Announcements/information

    View announcements from Otsuka Pharmaceutical.

Careers & Hiring

2 pages
  1. Career Autonomy Support/sustainability/support-for-career-independence

    This is Otsuka Pharmaceutical’s Sustainability page on “Career Autonomy Support.”

  2. Careers/recruit

    Please note that document screening for mid-career and disability employment applications may take some time. Thank you for your understanding.

Team

2 pages
  1. Employee Stories/company/otsuka-people-talk

    Hear from Otsuka Pharmaceutical employees.

  2. List of Executives/company/leadership

    Otsuka Pharmaceutical corporate information: List of Executives.

About

6 pages
  1. Corporate Information/company

    Otsuka Pharmaceutical corporate information.

  2. Global Satellite Research System/research-and-development/global-research-facilities

    This is the page about Otsuka Pharmaceutical’s research and development “Global Satellite System.”

  3. Philosophy/philosophy

    This is Otsuka Pharmaceutical’s Philosophy page.

  4. Research and Development/research-and-development

    Otsuka Pharmaceutical’s research and development.

Contact

2 pages
  1. Contact Us/contacts

    This is the “Contact” page on Otsuka Pharmaceutical’s website.

  2. Partnering and Licensing Activities/partnering-and-licensing/inquiry-form/form

    This is the “Partnering and Licensing Activities” page on Otsuka Pharmaceutical’s website.

Homepage

1 page
  1. Homepage/

    Otsuka Pharmaceutical is a total healthcare company that contributes to the health of people around the world through its two core businesses: Medical-Related Business and Nutraceuticals-Related Business.

Coverage

10 items
  1. Otsuka Announces Transformative Phase 3 FUSION Results for Ulefnersen, Bringing the FUS-ALS Community Closer to a Potential Targeted Treatment｜September 22, 2026｜News Releasesotsuka.co.jp/en/company/newsreleases/2026/20260922_1.html

    Otsuka Pharmaceutical announces Phase 3 FUSION results for ulefnersen, a potential targeted treatment for the FUS-ALS community.

    Sep 2026 · Otsuka Pharmaceutical Co., Ltd.News article

  2. Otsuka and Jolly Good Launch New Content for FACEDUO Dementia Care Support VR Understanding a New Perspective on Dementia｜September 18, 2026｜News Releasesotsuka.co.jp/en/company/newsreleases/2026/20260918_1.html

    Otsuka Pharmaceutical and Jolly Good launch new content for FACEDUO dementia care support VR, titled “Understanding a New Perspective on Dementia.”

    Sep 2026 · Otsuka Pharmaceutical Co., Ltd.News article

  3. Otsuka Presents New Phase 3b Results for SIMTRIYO® (centanafadine) Highlighting Consistent Improvements Across ADHD Symptoms, Anxiety, and Associated Features in Adults with ADHD and Comorbid Anxietyotsuka.co.jp/en/company/newsreleases/2026/20260924_1.html

    Otsuka Pharmaceutical presents new Phase 3b results for SIMTRIYO® (centanafadine), highlighting consistent improvements across ADHD symptoms, anxiety, and associated features. The findings concern adults with ADHD and comorbid anxiety.

    Sep 2026 · Otsuka Pharmaceutical Co., Ltd.News article

  4. Otsuka Pharmaceutical Completes Acquisition of Transcend Therapeutics｜June 15, 2026｜News Releasesotsuka.co.jp/en/company/newsreleases/2026/20260615_1.html

    Otsuka Pharmaceutical Co., Ltd News Releases

    Aug 2026 · Otsuka Pharmaceutical Co., Ltd.News article